SABS
SAB Biotherapeutics, Inc.Company Information
- Company Name
- SAB Biotherapeutics, Inc.
- CIK
- CIK0001833214
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- SABS: Nasdaq, SABSW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SABS
SEC filing data through
Insider Sentiment
- Last purchase
- 2023-12-07
- Last sale
- 2021-10-26
- Shares purchased (TTM)
- 17,740
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 68,448,750
- Shares outstanding
- 79,753,100
- Ownership
- 85.83%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -1.56%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 21 | 11 | 29 | 4 | 6 | 9 | 9 | 17 | 14 | 57 | 2 | ||||||
| Accounts Receivable Net Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Short Term Investments | 94 | 87 | 86 | 81 | 2 | 7 | 12 | 21 | 20 | 30 | 0 | - | ||||||
| Accrued Investment Income Receivable | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 4 | 2 | 4 | 3 | 3 | 2 | 2 | 3 | 2 | 1 | ||||||
| Assets Current | 108 | 113 | 101 | 113 | 9 | 16 | 24 | 33 | 40 | 47 | 59 | 3 | ||||||
| Deferred Finance Costs Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Long Term Investments | 105 | 110 | 47 | 51 | - | - | - | - | - | 1 | - | - | ||||||
| Operating Lease Right Of Use Asset | 2 | 3 | 3 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Finance Lease Right Of Use Asset | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Property Plant And Equipment Net | 14 | 14 | 13 | 13 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 21 | ||||||
| Assets | 238 | 248 | 173 | 183 | 30 | 38 | 44 | 54 | 62 | 71 | 84 | 28 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 4 | 3 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | ||||||
| Notes Payable Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 7 | 5 | 7 | 7 | 7 | 6 | 5 | 7 | 5 | 5 | 7 | 5 | ||||||
| Operating Lease Liability Current | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Deferred Income Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 1 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 12 | 10 | 11 | 11 | 11 | 10 | 8 | 9 | 8 | 8 | 11 | 9 | ||||||
| Operating Lease Liability Noncurrent | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Finance Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Derivative Liabilities Noncurrent | 7 | 6 | 6 | 2 | 2 | 1 | 6 | 4 | 4 | 6 | 12 | 0 | ||||||
| Liabilities | 23 | 21 | 21 | 18 | 18 | 17 | 18 | 17 | 16 | 19 | 27 | 13 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Treasury Stock Value | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | -6 | ||||||
| Additional Paid In Capital | 373 | 363 | 268 | 265 | 157 | 156 | 156 | 155 | 154 | 153 | 153 | 88 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | -0 | 0 | - | ||||||
| Retained Earnings Accumulated Deficit | -152 | -130 | -111 | -94 | -139 | -129 | -124 | -113 | -102 | -95 | -90 | -67 | ||||||
| Stockholders Equity | 215 | 227 | 151 | 165 | 12 | 21 | 26 | 37 | 46 | 53 | 57 | 15 | ||||||
| Liabilities And Stockholders Equity | 238 | 248 | 173 | 183 | 30 | 38 | 44 | 54 | 62 | 71 | 84 | 28 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 490 | ||||||
| Common Stock Shares Issued | 84 | 76 | 48 | 48 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | ||||||
| Shares Outstanding | 83 | 76 | 48 | 47 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 5 | ||||||
| Treasury Stock Common Shares | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSAB Biotherapeutics, Inc. (SABS) — SEC Financial Statements & Analysis
SAB Biotherapeutics, Inc. (SABS) is a biological products, (no diagnostic substances) company, incorporated in DE. SAB Biotherapeutics, Inc. trades on Nasdaq as: SABS, SABSW. SAB Biotherapeutics, Inc. (SABS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, SAB Biotherapeutics, Inc. carries a market cap of $311.04M, a P/E ratio of -24.35x, a P/B ratio of 1.45x, a P/S ratio of 186.82x, an enterprise value of $305.97M, and an EV/EBITDA multiple of -4.44x. On profitability, it posts a gross margin of 109.20%, an operating margin of -37657.07%, a net margin of 16338.56%, a Return on Equity (ROE) of -11.27%, a Return on Assets (ROA) of -9.52%, and a Return on Invested Capital (ROIC) of -64.88%. Per share, it reports EPS of $-0.16, diluted EPS of $-0.16, free cash flow per share of $-0.71, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -65.52% year-over-year, and EPS growth of -95.98% year-over-year. On the balance sheet, it maintains a current ratio of 9.22x, a quick ratio of 8.93x, working capital of $96.23M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, an interest coverage ratio of -309.79x, free cash flow of $-56.51M (TTM), and net debt of $-5.07M. Figures sourced from SEC EDGAR.
- Market Cap
- $311.04M
- P/E TTM
- -24.35x
- EPS TTM
- $-0.16
- P/B TTM
- 1.45x
- ROE TTM
- -11.27%
- ROA TTM
- -9.52%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-56.51M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is SAB Biotherapeutics, Inc. in?
SAB Biotherapeutics, Inc. (SABS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SABS trade on?
SAB Biotherapeutics, Inc. (SABS) trades on the Nasdaq.
Where is SAB Biotherapeutics, Inc. incorporated?
SAB Biotherapeutics, Inc. is incorporated in DE.
When was SAB Biotherapeutics, Inc. (SABS)'s most recent SEC filing?
SAB Biotherapeutics, Inc. (SABS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is SABS's market cap?
SAB Biotherapeutics, Inc. (SABS) has a market capitalization of $311.04M as of 2026-06-30.
What is SABS's EPS (earnings per share)?
SAB Biotherapeutics, Inc. (SABS)'s trailing twelve month EPS is $-0.16 as of 2026-06-30.
What is SABS's ROE (return on equity)?
SAB Biotherapeutics, Inc. (SABS)'s trailing twelve month Return on Equity (ROE) is -11.27% as of 2026-06-30.
What is SABS's ROA (return on assets)?
SAB Biotherapeutics, Inc. (SABS)'s trailing twelve month Return on Assets (ROA) is -9.52% as of 2026-06-30.
What is SABS's ROIC (return on invested capital)?
SAB Biotherapeutics, Inc. (SABS)'s trailing twelve month Return on Invested Capital (ROIC) is -64.88% as of 2026-06-30.
What is SABS's EV/EBITDA?
SAB Biotherapeutics, Inc. (SABS)'s trailing twelve month EV/EBITDA is -4.44x as of 2026-06-30.